Rifampin and posaconazole coadministration leads to decreased serum posaconazole concentrations

Clinical Infectious Diseases

Volumn 50, Issue 6, 2010, Pages 939-940

  Hohmann, Carina ^a   Kang, Elizabeth M ^b   Jancel, Timothy ^c  

^a KLINIKUM FULDA   (Germany)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; LINEZOLID; MICAFUNGIN; POSACONAZOLE; RIFAMPICIN; VANCOMYCIN;

ADULT; ASPERGILLOSIS; CASE REPORT; CHRONIC GRANULOMATOUS DISEASE; CLINICAL FEATURE; DIAGNOSTIC IMAGING; DRUG BLOOD LEVEL; HUMAN; LETTER; LIVER ABSCESS; MALE; OSTEOMYELITIS; PRIORITY JOURNAL; X CHROMOSOME LINKED DISORDER;

ANTIFUNGAL AGENTS; DRUG INTERACTIONS; HUMANS; MALE; RIFAMPIN; SERUM; TRIAZOLES; YOUNG ADULT;

EID: 77749277056     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/650740     Document Type: Letter

References (14)

1. 1. Krieter P, Flannery B, Musick T, Gohdes M, Martinho M, Courtney R. Disposition of posaconazole following single-dose oral ad-ministration in healthy subjects. Antimicrob Agents Chemother 2004; 48: 3543-3551. (Pubitemid 39129357)
2. Wang EJ, Lew K, Casciano CN, Clement RP, JohnsonWW. Interaction of common azole antifungals with P glycoprotein. Antimicrob Agents Chemother 2002; 46: 160-165.
3. 3. Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivistö KT. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet 2003; 42: 819-850. (Pubitemid 36995083)
4. Baciewicz AM, Chrisman CR, Finch CK, Self TH. Update on rifampin and rifabutin drug interactions. Am J Med Sci 2008; 335: 126-136.
5. 5. Drayton J, Dickinson G, Rinaldi MG. Coadministration of rifampin and itraconazole leads to undetectable levels of serum itraconazole. Clin Infect Dis 1994; 18: 266. (Pubitemid 24055281)
6. 6. Jaruratanasirikul S, Sriwiriyajan S. Effect of rifampicin on the pharmacokinetics of itraconazole in normal volunteers and AIDS patients. Eur J Clin Pharmacol 1998; 54: 155-158. (Pubitemid 28204269)
7. 7. Geist MJ, Egerer G, Burhenne J, Riedel KD, Mikus G. Induction of voriconazole metabolism by rifampin in a patient with acute myeloid leukemia: importance of interdisciplinary communication to prevent treatment errors with complex medications. Antimicrob Agents Chemother 2007; 51: 3455-3456. (Pubitemid 350067579)
8. 8. Krishna G, Parsons A, Kantesaria B, Mant T. Evaluation of the pharmacokinetics of posaconazole and rifabutin following co-administration to healthy men. Curr Med Res Opin 2007; 23: 545-552. (Pubitemid 46456902)
9. 9. Doostdar H, Grant MH, Melvin WT, Wolf CR, Burke MD. The effects of inducing agents on cytochrome P450 and UDP-glucuronyltransferase activities in human HEPG2 hepatoma cells. Biochem Pharmacol 1993; 46: 629-635. (Pubitemid 23262956)
10. Rae JM, Johnson MD, Lippman ME, Flockhart DA. Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays. J Pharmacol Exp Ther 2001; 299: 849-857.
11. 11. Walsh TJ, Raad I, Patterson TF, Chandrasekar P, Donowitz GR, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007; 44: 2-12. (Pubitemid 44968977)
12. 12. Ullmann AJ, Comely OA, Burchardt A, Hachem R, Kontoyiannis DP, et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother 2006; 50: 658-666. (Pubitemid 43190980)
13. Krishna G, Moton A, Ma L, Medlock MM, McLeod J. Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother 2009; 53: 958-966.
14. Thompson GR 3rd, Rinaldi MG, Pennick G, Dorsey SA, Patterson TF, Lewis JS 2nd. Posaconazole therapeutic drug monitoring: a reference laboratory experience. Antimicrob Agents Chemother 2009; 53: 2223-2224.